Future Ventures — cofounded by renowned VC Steve Jurvetson and Maryanna Saenko, a colleague of Jurvetson at his last firm, DFJ, as well as an investor previously with Airbus Ventures and Khosla Ventures — has closed its second fund with $200 million in capital commitments, say the pair.
In a wide-ranging conversation yesterday afternoon, Jurvetson characterized the fund as “dramatically oversubscribed in a fairly short period of time,” adding that roughly one-third of its investors are venture capitalists or other investors, that the “second largest bucket [comprises] tech executives, CEOs, and former CEOs of enormous companies of relevance to our ecosystem” and that the third of firm’s capital is coming from institutions, including one university endowment. (He didn’t specify which.)
As with Future’s $200 million debut fund, which closed two years ago, the outfit’s newest vehicle has a 15-year time horizon, giving it more leeway to make longer-term bets. Jurvetson also confirmed that as with that debut fund, Future features fairly standard economics, including charging 2.5% in management fees and 25% in carried interest, meaning the share of the profits that Future keeps from its investments.
“We tell our LPs, ‘Look, this is a long game, these companies take longer than five to seven years to come to full maturity, ” said Jurvetson, who has been on the board of SpaceX since 2009 and, along with three other directors, left the board of Tesla in September, following a 13-year run as a director. “They may go public in that timeframe. But as you can see with Tesla and SpaceX and some of the greatest tech stories of our day, you really would regret having feel pressured to punch out early when they’re really in the greatest phases of torrid growth.”
Undoubtedly, the fund could have been bigger. Jurvetson has been doing business with Elon Musk for more than 20 years, and beyond his early involvement with SpaceX and Tesla, Future participated in the first round of Musk’s tunnel-based transportation system, Boring Company.
It wrote the first check to Musk’s neurotechnology startup, Neuralink, which last summer unveiled its progress toward developing implantable brain-computer interfaces that include thousands of electrodes that Musk helps will eventually help to cure conditions like Alzheimer’s, dementia and spinal cord injuries, among other things.
Though SpaceX is now an 18-year-old company, Future has a stake in that business, too. In fact, Future’s first check went to Space X, and the firm last year raised a $100 million SpaceX SPV in just five days — capital that Saenko said came from most of the firm’s fund one investors, along with some additional investors who were able to get to know the firm through the process.
These pop-up type funds won’t happen routinely, according to Jurvetson. “We communicated in our fundraising that a special situation, maybe two, would occur where we do a later-stage, large check, single investment in a company we have immense conviction in, and we didn’t anticipate that to happen right away, but the opportunity to reopen the prior year’s round [in SpaceX] and join an extension of that close made it very tempting to do on behalf of the fund.”
Instead, the plan is to continue writing mostly small checks — $3.8 million on average — that represent the first checks raised by startups. The idea is to back around 20 companies from the new fund (as with the last) and to take a more relaxed view on board seats than might other firms. Part of that owes to necessity, suggests Saenko, noting that the two only have so much bandwidth, but also she said could “not think of a single situation where we’re not fully in the information flow of the company” even without a director role, which is often why VCs insist on one.
In the meantime, well beyond its Musk-related bets, Future has been assembling a portfolio that’s wide-ranging, with investments tied to cellular manufacturing, longevity, and edge AI, among other things.
Just yesterday, it was announced that it led a follow-on round in Sensei Biotherapeutics, a 21-year-old, Boston-based developer of personalized cancer drugs that’s planning a public offering this year and which uses bacteriophage to induce an adaptive immune response.
Future, which is also investor in the lab-grown meat producer Memphis Meats, is also very focused right now on regenerative agriculture and permaculture, which is an approach to land management that adopts arrangements observed in flourishing natural ecosystems. Said Saenko, “I think it would behoove all of us to look at our food industry and ask what are the ways in which we are currently feeding our global population that are unsustainable in the future, given the number of people that we have and are going to continue having on this planet,” she said.
What does not interest the pair are other trends sweeping the venture industry right now, from space investing to moving out of California.
On space investing, Jurvetson — who led DFJ’s investment in both SpaceX and the satellite company Planet — said it’s far too crowded at this point (“though I’m going to be a space tourist one day for sure”).
As for moving — as Musk did recently to Austin — Saenko isn’t going anywhere, she said, and neither is Jurvetson, who has already spent 12 years in Texas, including in high school, and calls it a “hellhole.”
“Sadly,” he said yesterday, “many of my friends have punched out and gone to Texas or Florida.” He berates them for it, too, added. “If you become wealthy enough as an investor or an entrepreneur such that you could choose to live anywhere you want in your life, why in the world would you pick up and go to some godforsaken place now? Just to avoid capital gains tax? How about, for example, donate to charity instead and avoid that capital gains tax?”
There is a “different way to look at the world rather than just trying to do wealth transfer and preservation across generations; that just feels so short sighted to me.”